Omalizumab for COPD patients with allergen sensitization and exposure
Official title: Clinical trial of omalizumab for allergen sensitized and exposed individuals with COPD
Funded at Johns Hopkins University · NIH-11624859 · Data updated 2026-11-12
A multicenter trial will test whether adding omalizumab helps people with COPD who are allergic to common indoor allergens and are exposed to them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 15, 2024 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $333,467 |
| NIH project number | 3U01AI177195-03S1 |
| Project ID | NIH-11624859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with COPD who are sensitized to indoor allergens and have documented exposure to those allergens.
✕Less likely to help
Patients without allergic sensitization or exposure to indoor allergens may not benefit from this approach.
What this research studies
This trial targets adults with COPD who also have allergic sensitization and exposure to indoor allergens. Participants will be randomly assigned to omalizumab or placebo in a double-blind setup across multiple centers. The goal is to see if omalizumab can improve COPD-related outcomes by addressing allergic inflammation. The study uses a phase 2, masked design to evaluate safety and signals of efficacy in this specific subgroup.
Why it matters
Potential benefit: If successful, participants may experience better COPD control and reduced adverse outcomes through a treatment that targets allergic inflammation.
How similar studies have gone: Previous studies show omalizumab benefits in allergic asthma and in COPD patients with specific allergic traits, supporting exploration in this overlap group.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Putcha, Nirupama — Johns Hopkins University
- Study coordinator: Putcha, Nirupama
Related research
Other NIH-funded projects on the same topics.
-
Clinical CT Imaging to identify and subtype pulmonary hypertension in COPD
A new CT imaging approach aims to help doctors detect and classify pulmonary hypertension in people with COPD.
-
Next-Generation Wearable AI for Precision COPD Risk and Care
A patient-centered project uses a smart wearable and AI to predict COPD flare-ups and support doctors in making better care decisions.
-
Ethics-aware Multimodal AI for COPD prevention, diagnosis, and treatment
A broad AI model uses diverse health data to help predict and manage COPD in people, with an emphasis on ethics and fairness.
-
Easier, local pulmonary rehab and social support for people with COPD in low-resource clinics
This project compares a 10-week community pulmonary rehabilitation program alone, the same program plus help with social needs, and usual care for people with moderate-to-severe COPD to see which helps people stick with rehab and feel better.
-
Improving COPD outcomes with real-world data
A doctor-scientist at a major university is using real-world information from COPD patients to understand which treatments work best, how safe they are, and whether people stick to their inhaler plans.
-
Helping people with COPD get diagnosed and treated when LDCT for lung cancer is done
A brief, patient-friendly program tests a tailored message and navigation help to encourage COPD diagnosis and management for people undergoing low-dose CT scans for lung cancer screening.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.